Trevi Therapeutics, Inc. (TRVI) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Trevi Therapeutics (TRVI) by buying shares or fractional shares at any major broker, or as one holding in a thematic basket. Trevi is a clinical-stage biopharmaceutical company with no approved products and no product revenue; its entire value rests on Haduvio (oral nalbuphine ER), an experimental therapy for chronic cough in idiopathic pulmonary fibrosis (IPF), other interstitial lung disease, and refractory chronic cough. It is a high-risk, binary, pre-revenue biotech where the stock tends to move on clinical trial data and regulatory milestones rather than earnings. As of November 20, 2026 the shares closed near $13.53, up about 14% for the year and 27% over one year but down about 25% over three months, for a market value of about $1.9 billion.
TRVI stock price
As of 2026-11-20, Trevi Therapeutics, Inc. (TRVI) last closed at $13.35, up 21.5% over the past year. Over the past 52 weeks it has traded between $9.99 and $19.50.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Trevi Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
TRVI key stats
At $13.35 on November 20, 2026, Trevi Therapeutics, Inc. (TRVI) has a market cap of $1.9B.
- Market cap
- $1.9B
- Price to book
- 6.3
- Beta
- 1.12
Market cap, P/E and yield are measured at the $13.35 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Trevi Therapeutics, Inc. (TRVI)?
The last two weeks for Trevi Therapeutics, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- TRVI closed at $13.35 on November 20, 2026, down 2.2% over the past five trading days (from $13.65).
- On November 9, 2026, Trevi Therapeutics, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 9, 2026, Trevi Therapeutics, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Trevi Therapeutics, Inc. (TRVI) do?
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing a single lead candidate, Haduvio (oral nalbuphine extended release), for chronic cough. Haduvio is designed to act on the cough reflex both centrally and peripherally as a kappa-opioid agonist and mu-opioid antagonist (a KAMA mechanism), a different approach from the P2X3 antagonists that most rivals pursue. Trevi is targeting three indications: chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC). The company has no marketed products and generates no product revenue, so it funds itself through equity raises and operates at a net loss, which is typical for a company at this stage.
The investment picture is a classic high-risk, high-reward clinical biotech. Trevi has reported positive mid-stage data: its Phase 2b CORAL trial in IPF-related chronic cough (N=165) met its primary endpoint across all dose groups in June 2025, and its Phase 2a RIVER trial in RCC showed a statistically significant reduction in cough frequency in March 2025. After an End-of-Phase 2 meeting with the FDA, Trevi started a Phase 3 program in IPF-related chronic cough and a Phase 2b trial in RCC in 2026. An April 2026 stock offering raised roughly $162 million in net proceeds, and Trevi ended September 2026 with about $299.4 million of cash and marketable securities, which management says funds operations into 2030. The Phase 3 program is called OCEAN: OCEAN-1 (52 weeks) started in the second quarter of 2026 with topline data expected in the first half of 2028, and OCEAN-2 (12 weeks) started in the third quarter with topline results expected in the second half of 2027. Both are recruiting. The Phase 2b LAKE trial in RCC began in the second quarter; its sample size re-estimation, once guided for the fourth quarter of 2026, is now expected early in the first quarter of 2027. In October 2026 Trevi said an FDA meeting produced overall alignment on a roughly 120-patient Phase 2 trial in non-IPF ILD-related cough, planned to start in the first quarter of 2027. Third-quarter results on November 9 showed a net loss of about $21.5 million ($0.13 per share, in line with estimates), up from $11.8 million a year earlier. The stock has been volatile: as of November 20, 2026 it closed near $13.53, up about 14% year to date and 27% over one year, but down about 25% over three months. The upside case is a first-in-class chronic cough drug in indications with no approved therapies; the downside case is that a late-stage trial fails or the FDA declines approval, which would remove most of the value underpinning the stock.
What's driving Trevi Therapeutics, Inc. (TRVI)?
1. Haduvio Phase 3 in IPF-related chronic cough.
The lead program advanced into Phase 3 in 2026 after positive Phase 2b CORAL data and overall alignment with the FDA at an End-of-Phase 2 meeting. IPF-related chronic cough has no approved therapy, so a successful Phase 3 followed by approval would give Trevi a first-in-class product. This readout is the single most important catalyst for the stock. The program is named OCEAN: the 12-week OCEAN-2 trial, started in the third quarter of 2026, is expected to read out first, in the second half of 2027, and the 52-week OCEAN-1 trial in the first half of 2028. Both trials were recruiting as of the November 2026 update. CORAL data were also accepted for an oral presentation at the CHEST 2026 annual meeting.
2. Refractory chronic cough expansion.
Trevi is also running a Phase 2b trial of Haduvio in refractory chronic cough (RCC), a far larger patient population, after its Phase 2a RIVER trial met its primary endpoint in 2025. RCC is a market that has frustrated larger competitors, and success here would materially widen Haduvio's commercial opportunity beyond the smaller IPF indication. The RCC trial, called LAKE, started in the second quarter of 2026 and includes a sample size re-estimation once half of participants complete treatment. That analysis was expected in the fourth quarter of 2026; in November Trevi moved it to early in the first quarter of 2027, based on projected enrollment, while keeping topline results in the second half of 2027. In September 2026 Oppenheimer said it viewed the re-estimation outcome as likely to be positive. For non-IPF ILD-related chronic cough, an October 2026 FDA meeting gave overall alignment on a Phase 2 dose-ranging trial (54 mg and 27 mg twice daily versus placebo, about 120 patients), expected to start in the first quarter of 2027 with topline data in the first half of 2028.
3. Differentiated mechanism.
Haduvio's kappa-agonist, mu-antagonist (KAMA) mechanism is distinct from the P2X3 antagonists that dominate rival chronic cough pipelines. Management highlights that Haduvio has shown statistically significant cough reductions across both IPF and RCC patients, a breadth its P2X3 peers have not consistently matched, which is the core of the differentiation thesis. The competitive field may be thinning: an October 2026 report said GSK halted development of camlipixant, one of the most advanced P2X3 candidates, around the time of Trevi's latest CORAL presentation.
4. Funded runway into 2030.
An April 2026 offering added roughly $162 million in net proceeds, and Trevi held about $299.4 million in cash and marketable securities at September 30, 2026, down from about $318.9 million in June, with a projected runway into 2030. Quarterly net loss widened to about $21.5 million in Q3 2026 (from $11.8 million a year earlier) as Phase 3 and Phase 2b trial spending lifted R&D expense to about $19.1 million from $10.1 million. That funding is meant to carry the company through its planned IPF and RCC readouts without an imminent need to raise more capital, reducing near-term dilution pressure.
What are the risks to Trevi Therapeutics, Inc. (TRVI)?
Trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. Even with a large cash balance, the company burns cash every quarter (the loss grew from about $13.2 million in Q1 2026 to $21.5 million in Q3) and will likely need additional financing before Haduvio could reach the market, and equity raises dilute existing shareholders (the April 2026 offering issued 11.6 million new shares). Timelines can slip, as the LAKE sample size re-estimation did when it moved from late 2026 into early 2027. Because Haduvio is derived from an opioid (nalbuphine), it faces scheduling, safety, and tolerability scrutiny that non-opioid rivals avoid. It also competes with well-capitalized programs from Merck, GSK, Bayer, and others. Insiders have sold some stock (one September 2026 filing showed about $596,000 of sales), and the shares are down about 25% over three months to November 20, 2026, a reminder of how quickly sentiment can swing without new data. Finally, the ~$1.9 billion market value already embeds significant expectations of clinical and regulatory success, so disappointing data could trigger a sharp decline.
What is the Trevi Therapeutics, Inc. (TRVI) forecast?
11 analysts publish price targets on TRVI, averaging $28.18 as of November 2026, or +111.1% against the $13.35 share price on November 20, 2026. The published targets run from $23.00 to $40.00, a moderate spread, and the ratings split 11 buy, 0 hold, 0 sell. Over the last six months there have been 5 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full TRVI forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is TRVI a buy or a sell?
We give no verdict on Trevi Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Haduvio Phase 3 in IPF-related chronic cough. The lead program advanced into Phase 3 in 2026 after positive Phase 2b CORAL data and overall alignment with the FDA at an End-of-Phase 2 meeting. The most optimistic published target, $40.00, assumes this works close to its best case.
The case against. Trevi is a single-asset, pre-revenue biotech, so its outcome is highly binary: a failed Phase 3 trial or an FDA rejection for Haduvio would eliminate most of the company's value. The most pessimistic target, $23.00, is roughly what TRVI is worth if this bites instead.
Read the full bull and bear case on TRVI, including what would have to change to break either one. Walnut is not an investment adviser.
Has Trevi Therapeutics, Inc. (TRVI) split its stock?
No. Trevi Therapeutics, Inc. (TRVI) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Trevi Therapeutics, Inc. (TRVI) valued?
Market cap, P/E and dividend yield at today's price are in the TRVI key stats above. The business figures below come from Trevi Therapeutics, Inc.'s reported results as of November 2026 and change when it next reports.
- Cash and marketable securities (Sept 30, 2026): ~$299 million
- Net loss (TTM): ~$61 million
- Q3 2026 net loss: ~$21.5 million (EPS -$0.13, in line)
- Product revenue (TTM): ~$0 (clinical stage, no approved products)
- Projected cash runway: into ~2030
As of November 2026: As a clinical-stage biotech, Trevi has no product revenue and runs at a net loss, so price-to-earnings does not apply. The roughly $1.9 billion market capitalization, about 6 times book value, reflects expectations for Haduvio's OCEAN and LAKE trials, with roughly $299 million of cash covering a meaningful slice of that value. Analysts expect a loss of about $0.49 per share for 2026 and $0.61 for 2027 as trials run; the average target of about $28 across 11 analysts sits well above the current price.
Who competes with Trevi Therapeutics, Inc. (TRVI)?
P2X3 antagonist chronic cough developers
The most direct competitors are large-cap and mid-cap companies developing P2X3 receptor antagonists for chronic cough, including Merck (gefapixant), GSK (camlipixant, acquired via Bellus Health), and Bayer (eliapixant). These programs target refractory chronic cough with a different mechanism than Haduvio, and several have deeper resources than Trevi. An October 2026 report said GSK halted development of camlipixant, which would remove one of the most advanced P2X3 rivals.
IPF and interstitial lung disease drug makers
In idiopathic pulmonary fibrosis, Trevi's Haduvio addresses the cough symptom rather than the underlying disease, but it operates alongside established antifibrotic makers such as Boehringer Ingelheim (nintedanib) and Roche (pirfenidone), plus a pipeline of newer IPF developers whose progress shapes the treatment options for these patients.
Other clinical-stage single-asset biotechs
As an investment, TRVI competes for capital with the broad universe of pre-revenue, single-product clinical-stage biotechs. These names share the same binary, catalyst-driven risk profile, where value depends on trial data and regulatory decisions rather than earnings, and where financing needs and dilution are recurring considerations.
What stocks are similar to Trevi Therapeutics, Inc. (TRVI)?
Other names that sit close to TRVI: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Trevi Therapeutics, Inc. (TRVI)
There are three common ways to get TRVI exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so TRVI sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where TRVI fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics is a single-asset, pre-revenue clinical-stage biotech whose ~$1.9 billion valuation (November 2026) prices in success for Haduvio in chronic cough, so returns hinge on the LAKE sample size re-estimation (now expected early in the first quarter of 2027), the Phase 3 OCEAN and Phase 2b LAKE readouts (from the second half of 2027) and eventual FDA action, not on current financial results.
More on Trevi Therapeutics, Inc. (TRVI)
Whether TRVI is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is TRVI a buy or a sell?, and where the stock could go from here in the TRVI stock forecast.
For income investors, whether TRVI pays a dividend and how the payout looks is covered in does TRVI pay a dividend? And to weigh TRVI against a peer, read the full side-by-side comparisons: TRVI vs GSK and TRVI vs BAYRY.
Wondering how TRVI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Trevi Therapeutics, Inc.
Ask Walnut's AI anything about TRVI and see how it fits what you own.
FAQ
What does Trevi Therapeutics do?
+
Trevi is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine extended release), an experimental therapy for chronic cough in idiopathic pulmonary fibrosis, other interstitial lung disease, and refractory chronic cough. It has no approved products yet.
Does TRVI make any money?
+
No. Trevi has no approved products and generates no product revenue. Like most clinical-stage biotechs, it operates at a net loss (about $61 million over the trailing twelve months to September 2026) and funds its research through cash raised in stock offerings, most recently about $162 million in net proceeds in April 2026.
What is Haduvio?
+
Haduvio is Trevi's lead drug candidate, an oral extended-release formulation of nalbuphine. It works on the cough reflex as a kappa-opioid agonist and mu-opioid antagonist (a KAMA mechanism), a different approach from the P2X3 antagonists used by many competing chronic cough programs.
How has Haduvio performed in clinical trials?
+
Trevi reported positive results in its Phase 2b CORAL trial in IPF-related chronic cough (N=165), which met its primary endpoint across all dose groups in June 2025, and in its Phase 2a RIVER trial in refractory chronic cough, which met its primary endpoint in March 2025. Phase 3 testing (the OCEAN program) and a Phase 2b RCC trial (LAKE) began in 2026, with first topline results expected in the second half of 2027. The LAKE sample size re-estimation is expected early in the first quarter of 2027.
Why is TRVI considered a high-risk stock?
+
Trevi depends almost entirely on one drug, Haduvio, and has no revenue. If a late-stage trial fails or the FDA declines to approve the drug, most of the company's value could disappear. Pre-revenue, single-asset biotechs are among the most volatile stocks.
How much cash does Trevi have?
+
Trevi held about $299.4 million in cash and marketable securities at September 30, 2026, after raising roughly $162 million in net proceeds in April 2026. Management has said this funds a projected cash runway into 2030.
Who are Trevi's main competitors?
+
In chronic cough, Trevi competes with P2X3 antagonist developers including Merck (gefapixant), GSK (camlipixant, which an October 2026 report said GSK has halted), and Bayer (eliapixant). In idiopathic pulmonary fibrosis, it operates alongside antifibrotic makers such as Boehringer Ingelheim and Roche, though Haduvio targets the cough symptom rather than the disease.
How can I invest in TRVI?
+
TRVI trades on the Nasdaq, so you can buy shares or fractional shares through any major brokerage, or hold it as one position in a thematic basket. Because it is a speculative clinical-stage biotech, some investors size such positions small relative to their overall portfolio. Walnut is not an investment adviser and this is not a recommendation.
How did Trevi do in its latest quarter?
+
For the third quarter of 2026, reported November 9, Trevi posted a net loss of about $21.5 million, or $0.13 per share, in line with estimates and up from $11.8 million a year earlier as R&D spending rose to about $19.1 million. It ended September with about $299.4 million of cash and marketable securities, started its OCEAN-2 Phase 3 trial, and pushed the LAKE sample size re-estimation to early 2027.
How has TRVI stock performed in 2026?
+
As of the November 20, 2026 close near $13.53, TRVI shares were up about 14% year to date and about 27% over one year, but down about 25% over three months (and up about 7% over the past month). The 52-week range is about $9.82 to $20.22. This is descriptive information, and Walnut is not an investment adviser.
When is Trevi's next clinical catalyst?
+
The next scheduled event is the sample size re-estimation for the Phase 2b LAKE trial in refractory chronic cough, expected early in the first quarter of 2027. Topline data from LAKE and the Phase 3 OCEAN-2 trial are expected in the second half of 2027, and OCEAN-1 in the first half of 2028.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Trevi Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.